Integrating necroptosis into pan-cancer immunotherapy: a new era of personalized treatment

Necroptosis has emerged as a promising biomarker for predicting immunotherapy responses across various cancer types. Its role in modulating immune activation and therapeutic outcomes offers potential for precision oncology.